

RECEIVED
CENTRAL FAX CENTER

JUN 24 2004

OFFICIAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. 10/057,857
Filed: January 23, 2002
Applicants: B. Nash Williams;
Michael D. McCully
Title: Genome Reading Device
Group Art Unit: 1631
Examiner: Marjorie A. Moran
Paper No.:
S.V.E.:
Attorney Docket: 1000.1

CERTIFICATE OF FAXING

I hereby certify that this AMENDMENT A IN RESPONSE TO OFFICE ACTION OF MARCH 24, 2004 and any documents referred to therein are being faxed to the United States Patent and Trademark Office to fax number 703-872-9306, on June 24, 2004.



Michael D. McCully
Signed: June 24, 2004

TRANSMITTAL OF AMENDMENT A
IN RESPONSE TO OFFICE ACTION OF MARCH 24, 2004

Box Non-Fee Amendment
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I enclose herewith AMENDMENT A IN RESPONSE TO OFFICE ACTION OF MARCH 24, 2004 for filing in the above-referenced application.

No additional fee is required.

Respectfully submitted,



Dated: June 24, 2004

Michael D. McCully
Registration No. 29,566
2424 East T.C. Jester, Suite 6206
Houston, Texas 77008-3483
Phone: 713-962-3178
Fax: 713-839-4565
E-mail: mmccully@ev1.net

OFFICIAL
RECEIVED
CENTRAL FAX CENTER
JUN 24 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. 10/057,857
Filed: January 23, 2002
Applicants: B. Nash Williams;
Michael D. McCully
Title: Genome Reading Device
Group Art Unit: 1631
Examiner: Marjorie A. Moran
Paper No.:
S.V.E.:
Attorney Docket: 1000.1

CERTIFICATE OF FAXING

I hereby certify that this AMENDMENT B and any documents referred to therein are being faxed to the United States Patent and Trademark Office to fax number 703-872-9306, on June 24, 2004.



Michael D. McCully
Signed: June 24, 2004

AMENDMENT A IN RESPONSE TO OFFICE ACTION OF MARCH 24, 2004

Box Non-Fee Amendment
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The Examiner has rejected original claims 1-16 under 35 USC § 112 1st, 2nd, and 6th paragraphs. Claims 1-11 are apparatus claims; claims 12-16 are directed to a method of genetic profiling, whereas the actual invention is actually a business method for utilizing known technology for analyzing a human (or other) genetic sample and comparing the sample genome with a database to correlate the sample genome with specific known physical/genetic conditions. Therefore, applicants have canceled claims 1-16 and replaced said claims with new claims 17-28, directed to a method of operating a DNA sequence database to provide individual professional and non-professional users medical/genetic information correlated to their specific DNA sequence structure.